Form 4: Mangoceuticals CEO Jacob Cohen Acquires 800,000 Shares as Bonus

Mangoceuticals CEO Jacob D. Cohen receives 800,000 shares as a bonus for fiscal year 2024.

Summary

• Jacob D. Cohen, CEO of Mangoceuticals, acquired 800,000 shares of common stock on June 3, 2024.
• These shares were issued as a bonus for fiscal year 2024 compensation.
• The shares were granted under the company's Amended and Restated 2022 Equity Incentive Plan.
• The Tiger Cub Trust, beneficially owned by Jacob D. Cohen, holds 8,275,000 shares.
• Mr. Cohen disclaims beneficial ownership of the securities held by The Tiger Cub Trust except to the extent of his pecuniary interest therein.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The CEO receiving a bonus in the form of shares suggests confidence in the company's performance and future prospects. However, it's a routine transaction.

Positives

• The acquisition of shares by the CEO demonstrates confidence in the company's future.
• The bonus structure aligns executive compensation with company performance.

Industry Context

This type of equity compensation is common in publicly traded companies to incentivize executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation is a standard practice across various industries, particularly in high-growth sectors.
• Companies like Tesla and Amazon have used stock options and grants extensively to attract and retain top talent.
• The size of the grant should be compared to similar companies in the pharmaceutical or nutraceutical industry to assess its competitiveness.

Stakeholder Impact

• The share acquisition could have a slightly positive impact on shareholder sentiment.
• Employees may view the bonus as a sign of company success.

Key Dates

Keywords

Mangoceuticals, Jacob D. Cohen, MGRX, share acquisition, CEO, bonus, equity incentive plan, Tiger Cub Trust, beneficial ownership